ホーム › 膵臓がん › バージニア › Arlington
Arlington、VAにおける膵臓がんの臨床試験
Arlingtonとその周辺地域（約30マイル以内）の拠点で、膵臓がんに関する33件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
被験者募集中第3相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
被験者募集中第1/2相
- NEXT Virginia, Fairfax · 11マイル先
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Fairfax · 11マイル先
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology Virginia, Fairfax · 11マイル先
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
被験者募集中第3相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
被験者募集中第3相
- Investigative Site US057, Fairfax · 11マイル先
- Investigative Site US065, Fairfax · 11マイル先
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
被験者募集中第3相
- Inova Schar Cancer Institute Clinical Trials, Fairfax · 11マイル先
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- NEXT Oncology Virginia, Fairfax · 11マイル先
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- Next Oncology Virginia Cancer Specialist, Fairfax · 11マイル先
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
被験者募集中第1相
- NEXT - Virginia, Fairfax · 11マイル先
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology, Fairfax · 11マイル先
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
被験者募集中観察研究
- Inova Fairfax Hospital, Falls Church · 4マイル先
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
被験者募集中第2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
被験者募集中第1相
- Virginia Cancer Specialists, PC, Fairfax · 11マイル先
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
被験者募集中第3相
- Inova Fairfax Hospital, Falls Church · 4マイル先
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
Pancreatic Cancer Early Detection Consortium
被験者募集中観察研究健康なボランティア歓迎
- Inova Schar Cancer Institute, Fairfax · 11マイル先
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax · 11マイル先
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Fairfax · 11マイル先
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- NEXT Oncology Virginia, Fairfax · 11マイル先
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- NEXT Virginia, Fairfax · 11マイル先
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
被験者募集中第3相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Next Oncology Virginia, Fairfax · 11マイル先
A 2-part Phase 1/2 Open-label Trial on ODM-212
被験者募集中第1/2相
- NEXT Oncology Virginia, Fairfax · 11マイル先
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
被験者募集中第1/2相
- NEXT Virginia, Fairfax · 11マイル先
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- NEXT Virginia, Fairfax · 11マイル先
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
被験者募集中第1/2相
- NEXT, Virginia, Fairfax · 11マイル先
他の都市における膵臓がんの試験
- Houston, TX61件の研究
- New York City, NY60件の研究
- Boston, MA43件の研究
- Nashville, TN39件の研究
- Los Angeles, CA35件の研究
- St. Louis, MO33件の研究
- Baltimore, MD31件の研究
- San Antonio, TX31件の研究
- Philadelphia, PA26件の研究
- Tampa, FL26件の研究
- Durham, NC24件の研究
- San Diego, CA24件の研究
Arlingtonにおける他の研究
- 非小細胞肺癌104件の研究
- 転移性癌53件の研究
- 大腸癌52件の研究
- がん（全種類）48件の研究
- 乳がん47件の研究
- 卵巣がん46件の研究
- 肺がん41件の研究
- 子宮内膜がん39件の研究
- 頭頸部扁平上皮癌26件の研究
- 小細胞肺がん23件の研究
- 胃癌20件の研究
- トリプルネガティブ乳がん20件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。